Pfizer

1Q Revenues: $14.6 billion (+45%)

1Q Earnings: $4.9 billion (+45%)

Comments: Vaccines sales were $4.9 billion in the quarter, up from $1.6 billion in 1Q20 driven by BNT162b2, which contributed $3.5 billion in global revenues. Excluding BNT162b2, revenues grew 8%. Eliquis revenue was up 25% operationally to $1.6 billion. Oncology sales were up 18% to $2.9 billion. Internal Medicine sales were up 11% to $2.6 billion. Hospital sales were up 12% to $2.3 billion. Inflammation & Immunology sales were up 9% to $1.1 billion. Rare Disease revenues were up 29% to $824 million. Vyndaqel/Vyndamax globally was up 88% to $453 million. Xeljanz globally was up 18% to $538 million. Xtandi sales were up 28% to $267 million. Inlyta globally was up 34% to $229 million. Biosimilars, which grew 79% to $530 million. Prevnar 13 sales were $1.3 billion, down 11%, primarily driven by a 57% decline due to disruptions to wellness visits due to COVID-19, including delaying other vaccinations. Ibrance sales were down 1% to $1.3 billion. Chantix sales were down 21% to $217 million.